A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors

Clinical trial NCT01226732 · COMPLETED

Trial details

NCT number: NCT01226732
Sponsor: SCRI Development Innovations, LLC
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Metastatic or Unresectable Solid Tumor Malignancy

Start date: 2010-11-01
Primary completion: 2013-07-01
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.